These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 32990110

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M, Raap U, Staubach P, Richter-Huhn G, Bauer A, Oppel EM, Hillen U, Baeumer D, Reinhardt M, Chapman-Rothe N.
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [Abstract] [Full Text] [Related]

  • 7. Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
    Marín-Cabañas I, Berbegal-de Gracia L, de León-Marrero F, Hispán P, Silvestre JF.
    Actas Dermosifiliogr; 2017 May; 108(4):346-353. PubMed ID: 28219634
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria.
    Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F.
    Pediatr Allergy Immunol; 2021 Jan; 32(1):153-160. PubMed ID: 32745323
    [Abstract] [Full Text] [Related]

  • 10. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
    Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Yagami A, Stjepanovic A, Radin A, Staudinger HW, Patel N, Amin N, Akinlade B, Fan C, Bauer D, Yancopoulos GD, Patel K, Mannent LP, Laws E.
    J Allergy Clin Immunol; 2024 Jul; 154(1):184-194. PubMed ID: 38431226
    [Abstract] [Full Text] [Related]

  • 11. Factors Associated With Refractoriness to an Up to Fourfold Dosage of Antihistamines in Isolated Chronic Spontaneous Urticaria.
    Wongjirattikarn R, Chaowattanapanit S, Foocharoen C, Sawanyawisuth K, Choonhakarn C, Julanon N, Utchariyaprasit E.
    J Cutan Med Surg; 2022 Jul; 26(6):593-599. PubMed ID: 36172833
    [Abstract] [Full Text] [Related]

  • 12. From Research to Practice: The Latest Data on Evolving Treatments for Chronic Spontaneous Urticaria.
    Gooderham MJ, Kwatra SG, Geng B.
    J Drugs Dermatol; 2024 Sep 01; 23(9):795-806. PubMed ID: 39231089
    [Abstract] [Full Text] [Related]

  • 13. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine.
    Curto-Barredo L, Giménez-Arnau AM.
    G Ital Dermatol Venereol; 2019 Aug 01; 154(4):444-456. PubMed ID: 30717573
    [Abstract] [Full Text] [Related]

  • 14. Risk factors of uncontrolled symptoms using the standard dose of second-generation H1 -antihistamines in chronic spontaneous urticaria children.
    Koosakulchai V, Yuenyongviwat A, Sangsupawanich P.
    Asian Pac J Allergy Immunol; 2022 Jun 01; 40(2):121-125. PubMed ID: 32061244
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W, Hu S, Li M, Yang L, Liu L, Zheng M, Guo Z, Song Z, Zhang C, Diao Q, Xu J, Richard A, Patwardhan M, Lyu T, Uddin A, Fogel R, Ligueros-Saylan M, Zheng J.
    Dermatol Ther; 2022 Apr 01; 35(4):e15303. PubMed ID: 34984792
    [Abstract] [Full Text] [Related]

  • 16. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Grekowitz E, Metz M, Altrichter S, Bauer A, Brockow K, Heine G, Lionnet L, Saday KK, Hultsch T, Søerensen OE, Maurer M.
    Br J Dermatol; 2024 May 17; 190(6):825-835. PubMed ID: 38308655
    [Abstract] [Full Text] [Related]

  • 17. An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria.
    Ayse Ornek S, Orcen C, Church MK, Kocaturk E.
    Int Immunopharmacol; 2022 Nov 17; 112():109198. PubMed ID: 36115277
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H, Baeck M, Stockman A, Sabato V, Grosber M, Moutschen M, Lambert J, Vandebuerie L, de Montjoye L, Rabijns H, Allewaert K, Schrijvers R.
    J Eur Acad Dermatol Venereol; 2020 Jan 17; 34(1):127-134. PubMed ID: 31099916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.